BioSpace News Archive

The intermittent catheter is a type of urological catheter and it is used among urine retention patients to drain urine from the urinary bladder.

In an ongoing series of research conducted by KMK Consulting, Inc. covering Innovation & Customer Value, Allergan and Bausch Health (backed by its Salix division) were ranked as the top companies best poised to deliver therapeutic innovation in the IBS market. T

Villanova University President the Rev. Peter M. Donohue, OSA, PhD, announced the appointment of Michele Marcolongo, PhD, PE, as the Drosdick Endowed Dean of the College of Engineering, effective July 31.

Coronavirus Workforce Preparedness Training, the first comprehensive business training program for COVID-19, has been launched by the Corporate Health and Wellness Association (CHWA).

Radians, a top-tier manufacturer of quality Personal Protective Equipment, donated over 14,000 N95 masks to its hometown Memphis.

While the COVID-19 epidemic is ongoing in Europe, China has already won the staged victory with scientific method to fight against COVID-19. According to the latest official data, the infection situation in China has been initially controlled and only a few or even no new cases have been reported over the past several days.

The management team will host a conference call today, Thursday, March 26th in English at 2:30 pm EDT (New York time) / 7:30 pm CET (Paris time). A presentation will be available in the Investors section of the Poxel website.

Tabula Rasa HealthCare®, Inc. (“TRHC”) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, has named Frank Sparacino Senior Vice President of Investor Relations and Corporate Development.

BioDuro LLC, a leading global life sciences contract research and development organization, announced today that it has initiated a COVID-19 nanobody therapeutic program, leveraging the company’s biologics discovery platform and a specialized COVID-19 dedicated team.

OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today reported its consolidated annual financial results for 2019 and provided an update on key achievements, as well as the company’s outlook for its agonist and antagonist immunotherapies for cancers and autoimmune diseases.